Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial.
Guarneri V, Giorgi CA, Cinieri S, Bengala C, Mariani G, Bisagni G, Frassoldati A, Zamagni C, De Rossi C, Amoroso V, Andreetta C, Ferro A, Zambelli A, Gori S, Garrone O, Dieci MV, Orlando L, Pastina I, Beninato T, Moretti G, Genovesi E, Cinefra M, Vicini R, Magni G, De Salvo GL, Conte P. Guarneri V, et al. Among authors: bisagni g. Eur J Cancer. 2021 Sep;154:21-29. doi: 10.1016/j.ejca.2021.05.008. Epub 2021 Jul 2. Eur J Cancer. 2021. PMID: 34225066 Free article. Clinical Trial.
Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
Cocconi G, Bisagni G, Ceci G, Bacchi M, Boni C, Brugia M, Carpi A, Di Costanzo F, Franciosi V, Gori S, et al. Cocconi G, et al. Among authors: bisagni g. J Clin Oncol. 1992 Jun;10(6):984-9. doi: 10.1200/JCO.1992.10.6.984. J Clin Oncol. 1992. PMID: 1588379 Clinical Trial.
Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC).
Boni C, Savoldi L, Bisagni G, Ceci G, Crinò L, De Lisi V, Di Costanzo F, Lasagni L, Manenti AL, Moretti G, Rondini E, Sassi M, Zadro A. Boni C, et al. Among authors: bisagni g. Eur J Cancer. 1998 Nov;34(12):1974-6. doi: 10.1016/s0959-8049(98)00231-7. Eur J Cancer. 1998. PMID: 10023325 Clinical Trial.
Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study.
Cocconi G, Bisagni G, Bella M, Acito L, Anastasi P, Carpi A, Di Costanzo F, Frassoldati A, Mosconi A, Borrini A, Buzzi P. Cocconi G, et al. Among authors: bisagni g. Am J Clin Oncol. 1999 Dec;22(6):593-600. doi: 10.1097/00000421-199912000-00010. Am J Clin Oncol. 1999. PMID: 10597744 Clinical Trial.
Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G, Di Blasio B, Boni C, Bisagni G, Ceci G, Rondini E, Bella M, Leonardi F, Savoldi L, Camisa R, Bruzzi P. Cocconi G, et al. Among authors: bisagni g. Cancer. 2002 Jul 15;95(2):228-35. doi: 10.1002/cncr.10678. Cancer. 2002. PMID: 12124820 Free article. Clinical Trial.
110 results